BCAL Diagnostics Limited (ASX:BDX)

Market Cap	28.39M -26.1%
Revenue (ttm)	2.54M -1.3%
Net Income	-7.16M
EPS	-0.02
Shares Out	368.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,840
Average Volume	138,895
Open	0.0750
Previous Close	0.0830
Day's Range	0.0750 - 0.0780
52-Week Range	0.0520 - 0.1550
Beta	0.82
RSI	47.61
Earnings Date	May 25, 2026

About BCAL Diagnostics

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BDX

Financial Performance

In fiscal year 2025, BCAL Diagnostics's revenue was 2.65 million, a decrease of -13.01% compared to the previous year's 3.05 million. Losses were -7.24 million, 13.1% more than in 2024.